Sign in

NCT06264336Completed

Effects of High-intensity Gait Training on Fatigue, Gait, and Neuroplasticity in People With Multiple Sclerosis

Source: ClinicalTrials.gov · Last updated 7 May 2026

Brief summary (registry, in English)

Nearly 1 million individuals in the United States have multiple sclerosis, which causes fatigue and problems with walking. Fatigue and walking problems are poorly treated, but exercise training, particularly high-intensity walking exercise, may help. This provide insight into whether high-intensity walking exercise can improve fatigue and walking problems in people with multiple sclerosis, which could improve quality of life and reduce economic burden.

Status (registry)
Completed
Study type
Interventional
Enrollment
12 (actual)
First submitted
1 Feb 2024
Start date
1 Mar 2024
Primary completion date
31 Mar 2026
Lead sponsor
University of Illinois Chicago
NCT number
NCT06264336

What you commit to

  • Study type: Interventional
  • Participants enrolled: 12
  • From 1 Mar 2024 to the primary completion date, 31 Mar 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Metal implants in the head or face

Other illness

  • Other neurological disorders besides multiple sclerosis
  • Cardiorespiratory or metabolic diseases (e.g., cardiac arrhythmia, uncontrolled hypertension or diabetes, chronic emphysema)
  • Significant cognitive or communication impairment (Mini-Mental State Examination (MMSE)\<21), which could impede the understanding of the purpose of procedures of the study or prevent the patient from performing the ankle-tracking task.
  • Failure to pass the graded exercise stress test
  • Implanted cardiac pacemaker
  • History of seizures or epilepsy
  • Currently under medication that could increase motor excitability and lower seizure threshold

Other

  • Adults unable to consent
  • Pregnant women
  • Prisoners
  • Multiple sclerosis relapse within the last 30 days
  • Severe osteoporosis
  • Unexplained, recurring headaches
  • Skull abnormalities or fractures
  • Concussion within the last 6 months

Who the study is looking for

  • Age ≥21 years
  • Multiple sclerosis diagnosis
  • Stable disease-modifying therapy (DMT) over the past 6 months
  • Walking dysfunction (i.e., abnormal gait pattern, Expanded Disability Status Scale (EDSS) score of 4-6.5, and/or Patient-determined disease steps (PDDS) score of 3-6)
  • Able to walk for 6 minutes at self-paced speed. Handheld assistive device is acceptable.
  • Symptomatic fatigue (Fatigue Severity Score ≥ 4)

Age in the registry: 21 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of Illinois Chicago
Coordinator of this site? Confirm its status		ChicagoUnited StatesUnknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.